<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82569">
  <stage>Registered</stage>
  <submitdate>28/01/2008</submitdate>
  <approvaldate>30/01/2008</approvaldate>
  <actrnumber>ACTRN12608000058370</actrnumber>
  <trial_identification>
    <studytitle>A randomised, double blinded, placebo controlled trial of the effect of self administered methoxyflurane using the Penthrox® Inhaler on tolerance of the Computed Tomography (CT) Enteroclysis procedure</studytitle>
    <scientifictitle>For patients undergoing Computed Tomography (CT) Enteroclysis, self administered methoxyflurane via the Penthrox® inhaler may be better than placebo at improving patient tolerance of the procedure</scientifictitle>
    <utrn />
    <trialacronym>Penthrox for CTE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>CT enteroclysis tolerance</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Methoxyflurane (Penthrox) is self administered by inhalation via the Penthrox Inhaler immediately before commencing the procedure. Patients can consume up to 1 vial (3 mL) of Penthrox.</interventions>
    <comparator>Placebo is used in the form of Normal Saline. This is self administered by inhalation via the Penthrox inhaler immediately before commencing the procedure.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall patient comfort or discomfort during Computed Tomography Enteroclysis (CTE) as measured on a 10cm visual analogue scale</outcome>
      <timepoint>1 hour post procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient comfort or discomfort during specific stages of the Computed Tomgraphy (CTE) procedure (nasoduodenal intubation, enteric contrast infusion, CT scan)</outcome>
      <timepoint>1 hour post procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Referred for CT enteroclysis 
Age 16 years or older
Able to give written informed consent themselves</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known pre-existing renal or hepatic impairment: serum creatinine = 1.5 x upper limit of normal range (ULNR) or bilirubin = 2 x upper limit of normal range (ULNR).
Concomitant use of any of the following medications: tetracyclines, gentamicin, kanamycin, colistin, polymyxin b, cephaloridine or amphotericin b.
Personal or familial hypersensitivity to fluorinated anaesthetics.
Personal or familial malignant hyperthermia.
Pre-medication with anxiolytic eg. midazolam, diazepam.
Pre-medication with breakthrough dose of analgesic eg. paracetamol plus codeine or oxycodone.
Hypotension pre-procedure: systolic blood pressure &lt;90 mmHg.
Bradycardia pre-procedure: heart rate &lt;50 bpm.
Poor oxygen saturation pre-procedure: O2 saturation &lt;90%.
Pregnancy: currently pregnant or attempting to become pregnant.
Lactation: currently breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Alan Moss, Principal Investigator, Penthrox for CTE trial</primarysponsorname>
    <primarysponsoraddress>Department of Gastroenterology
Box Hill Hospital
Nelson Rd
Box Hill, Victoria 3128</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medical Developments International Limited</fundingname>
      <fundingaddress>7/ 56 Smith Rd 
Springvale, Victoria 3171</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Eastern Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Alan Moss</name>
      <address>Department of Gastroenterology
Box Hill Hospital
Nelson Rd
Box Hill, Victoria 3128</address>
      <phone>61 3 9895 3333</phone>
      <fax />
      <email>alan.moss@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alan Moss</name>
      <address>Department of Gastroenterology
Box Hill Hospital
Nelson Rd
Box Hill, Victoria 3128</address>
      <phone>61 3 9895 3333</phone>
      <fax />
      <email>alan.moss@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alan Moss</name>
      <address>Department of Gastroenterology
Box Hill Hospital
Nelson Rd
Box Hill, Victoria 3128</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>